Abstract:Abstract Purpose: We evaluated the performance of the longitudinal-radiomics of multi-parametric magnetic resonance imaging (MRI), developed and validated based on a multicenter dataset adopting a radiomic strategy, for prediction of treatment response to neoadjuvant chemotherapy (NAC) in breast cancer. Methods and materials: We analyzed clinical and pathological data of patients with breast cancer and compared machine-learning classification algorithms in predicting treatment response following NAC from four hospitals (primary cohort and external validation cohort 1-3) between July 2015 and December 2021. Patients were monitored with MRI before (pretreatment) and after (mid-treatment) three or four cycles of NAC. Longitudinal-radiomics analysis was performed at pre- and mid-treatment dynamic contrast-enhanced, T2-weighted imaging, and diffusion-weighted imaging mapping by using 3D Slicer software. Radiomics features were extracted from original and filtered images using PyRadiomics (V3.0.1) filtered images were generated using Laplacian of Gaussian and wavelet filters. The stacking strategy including LR, LDA and SVM (radial basis function) were used to combined the results of the base models, and gave a secondary prediction result. Results: In total, 1048 cases were enrolled in the study. In identifying the residual cancer burden (RCB) 0 v.s. RCB 1-3, longitudinal-radiomic models achieved the highest area under the receiver operating characteristic curve (AUC) of 0.909 and 0.893 in the training and test sets. The accuracies of the stacking-SVM classifier were 84.3% (86/102), 75.6% (205/271) and 77.9% (265/340) in the external validation set. In identifying the RCB 3 v.s. RCB 0-2, longitudinal-radiomic models achieved the highest AUC of 0.981 and 0.923 in the training and test sets. In the external validation set, the performance was with accuracy=91.2%-92.2%. The cascade model also stratified 78.9%, 69.1% and 76.1% of the RCB 1-2 patients into RCB 1-2 prediction group to receive suitable NAC and feasible breast-conserving surgery. Our findings showed high predictive ability and reproducibility across multicenter dataset. By two-step prediction results of cascade models, the patient could be assigned to one of the three groups corresponding to three RCB status: RCB 0, RCB 1-2, or RCB 3. In this way, using the cascade models, some of RCB 3 patients may allow treatment to be tailored for optimal outcomes. RCB 0 and RCB 1-2 groups could receive suitable NAC and feasible breast-conserving surgery. Conclusion: In conclusion, our study had good predictive ability for RCB assessment, which could help clinicians guide individualized treatment options for breast cancer patients in NAC. The application of stacking cascade model may have the potential to further reduce unnecessary NAC and economic costs associated with current breast cancer management. Figure 1. The flowchart of the study. This was a multicenter study with patients retrospectively enrolled from four medical centers in different cities of China. Pretreatment and midtreatment multi-parametric MRI (DCE, T2WI, and DWI) and clinical information were proposed to predict treatment response to NAC in patients with primary invasive breast cancer. The data from Foshan was used as the primary cohort (PC), and the other three data sets were used as independent validation cohorts (VC). This study included radiomic feature engineering, model building, model comparison and clinical application. Figure 1. The flowchart of the study. This was a multicenter study with patients retrospectively enrolled from four medical centers in different cities of China. Pretreatment and midtreatment multi-parametric MRI (DCE, T2WI, and DWI) and clinical information were proposed to predict treatment response to NAC in patients with primary invasive breast cancer. The data from Foshan was used as the primary cohort (PC), and the other three data sets were used as independent validation cohorts (VC). This study included radiomic feature engineering, model building, model comparison and clinical application. Figure 2. ROC curves among different radiomic signatures and among different models in identifying the RCB 0 vs RCB 1-3. RCB, residual cancer burden; ROC, receiver operating characteristic; SVM, support vector machine; RF, random forest; MLP, multilayer perceptron; LR, logistic regression. Figure 2. ROC curves among different radiomic signatures and among different models in identifying the RCB 0 vs RCB 1-3. RCB, residual cancer burden; ROC, receiver operating characteristic; SVM, support vector machine; RF, random forest; MLP, multilayer perceptron; LR, logistic regression. Figure 3. ROC curves among different radiomic signatures and among different models in identifying the RCB 3 vs RCB 0-2. RCB, residual cancer burden; ROC, receiver operating characteristic; SVM, support vector machine; RF, random forest; MLP, multilayer perceptron; LR, logistic regression. Figure 3. ROC curves among different radiomic signatures and among different models in identifying the RCB 3 vs RCB 0-2. RCB, residual cancer burden; ROC, receiver operating characteristic; SVM, support vector machine; RF, random forest; MLP, multilayer perceptron; LR, logistic regression. Citation Format: wei li, Yuhong huang, teng zhu, zhiyong wu, ying lin, guolin ye, Kun Wang. Multiparametric MRI-based Longitudinal-radiomics Analysis for Early Prediction of Treatment Response of Breast Cancers to Neoadjuvant Chemotherapy: A Multicenter Study [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-01-19.

Abstract P5-02-35: Radiomic biomarkers to predict the efficacy of anti-PD-1 immunotherapy-based combinational treatment in advanced breast cancer: a multi-center study

A Radiomic Approach to Access Tumor Immune Status by CD8<SUP>+</SUP>TRMs on Surgically Resected Non-Small-Cell Lung Cancer

Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study

Radiomics Model Based on Intratumoral and Peritumoral Features for Predicting Major Pathological Response in Non-Small Cell Lung Cancer Receiving Neoadjuvant Immunochemotherapy

Radiomics Models Derived From Arterial-Phase-Enhanced CT Reliably Predict Both PD-L1 Expression and Immunotherapy Prognosis in Non-small Cell Lung Cancer: A Retrospective, Multicenter Cohort Study

A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study

Abstract PR-03: Radiomics and AI-based Treatment Decision Support for Non-Small Cell Lung Cancer

Abstract OT3-02-03: Radiomics Multi-Parametric MRI of Before and after Neoadjuvant Chemotherapy Associated with Axillary Lymph Node Metastasis and Prognostic in Patients with Breast Cancer: A Multicenter RBC-002 Study

Radiomics of multi-parametric MRI associated with axillary lymph node metastasis and prognostic in patients with breast cancer: A multicenter RBC-001 study

Abstract 5619: Radiomics-based machine learning models to predict progression and biomarker status in non-small cell lung cancer (NSCLC) patients treated with immunotherapy

Assessing the robustness of radiomics/deep learning approach in the identification of efficacy of anti-PD-1 treatment in advanced or metastatic non-small cell lung carcinoma patients

Abstract P6-01-19: Multiparametric MRI-based Longitudinal-radiomics Analysis for Early Prediction of Treatment Response of Breast Cancers to Neoadjuvant Chemotherapy: A Multicenter Study

Pretreatment Radiomic Biomarker for Immunotherapy Responder Prediction in IB-IV Stage NSCLC: A Multi-Center Retrospective Study

JCSE01.18 A CT-Based Radiomics Approach to Predict PD1 Inhibitor Response in Non-Small-Cell Lung Cancer

P1.01-66 A CT-Based Radiomics Approach to Predict PD1 Inhibitor Response in Non-Small-Cell Lung Cancer

A Machine Learning Algorithm for Predicting Therapeutic Response to Anti-PD1

Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study

Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer

Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

CT-Based Peritumoral and Intratumoral Radiomics as Pretreatment Predictors of Atypical Responses to Immune Checkpoint Inhibitor Across Tumor Types: A Preliminary Multicenter Study